Novo's $349 Wegovy: Who It Beats, Who It Doesn't
Novo Nordisk cut Wegovy to $349/month in November. Five months later, the market has absorbed the shock. Here's exactly which providers lost, which ones survived, and where the $199 intro offer actually moves the needle.
Bottom Line
At $349/month, Novo's Wegovy beats every compounded semaglutide program priced above $249 on a value-per-dollar basis — you get FDA oversight for the same price as mid-tier compounded. It still loses to compounded programs at $149–199 on raw cost. The $199 intro price (first 2 months, lowest doses) is a true loss leader — take it if you're eligible.
On November 17, 2025, Novo Nordisk cut the NovoCare cash-pay price of Wegovy from $499 to $349 per month. Same medication. Same FDA-approved pen. Thirty percent less money.
The announcement was the second-biggest event in GLP-1 pricing history (the first was the 2024 list price setting). And it wasn't subtle — Novo extended the $349 price to Costco, GoodRx, WeightWatchers, Ro, LifeMD, eMed, and any retail pharmacy that wanted to honor it. Access went national overnight.
Five months in, here's what the damage looks like.
Who got crushed: the $249–299 compounded tier
Sprout Health at $249/month for compounded semaglutide was a reasonable pick in October 2025. In April 2026, it's competing directly against $249/month brand-name Wegovy (Novo's 12-month plan). The decision becomes: "Same price. One is FDA-approved. One isn't." That's not a hard decision.
Zealthy at $297/month is in the worst position — paying more for compounded than you'd pay for the brand. Unless a patient specifically wants Zealthy's bundled coaching or 30-day guarantee, the math no longer works.
Providers priced $250+ need to either:
- Cut prices aggressively (Eden dropped to $149 first-month)
- Differentiate on format (SHED's drops and lozenges, which Wegovy can't offer)
- Shift to tirzepatide (where Zepbound's self-pay starts at $299/mo for 2.5mg only)
- Accept they're now a premium-service play, not a budget play
Who survived: the sub-$200 compounded tier
Here's the break-even math. Over 12 months:
| Option | 12-Month Cost | Savings vs. $349 Wegovy |
|---|---|---|
| Yucca Health ($146/mo) | $1,752 | –$2,436 |
| MEDVi ($179/mo) | $2,148 | –$2,040 |
| Breeze Meds ($189/mo) | $2,268 | –$1,920 |
| SHED / Care Bare ($199/mo) | $2,388 | –$1,800 |
| Synergy Rx ($200/mo) | $2,400 | –$1,788 |
| Novo Wegovy 12-mo ($249/mo) | $2,988 | –$1,200 |
| Sprout Health ($249/mo) | $2,988 | –$1,200 |
| NovoCare Wegovy ($349/mo) | $4,188 | baseline |
Yucca Health saves you $2,436 annually over NovoCare Wegovy — roughly the price of another four months of brand-name medication. That's still a meaningful gap. The sub-$200 tier remains the value floor.
The $199 intro offer: where it actually matters
Alongside the $349 standard price, Novo launched a $199/month intro price for the first two months of the two lowest Wegovy and Ozempic doses (0.25mg and 0.5mg). It runs from November 17, 2025 through June 30, 2026.
The intro isn't a long-term savings play — it's a sampling mechanism. If you tolerate the medication well in months 1–2, you either stay brand-name at $349 or migrate to a cheaper compounded provider for month 3+. If you don't tolerate it, you exit cleanly without having overpaid.
Who should pay for Wegovy now
At $349/month standard pricing, brand-name Wegovy makes the most sense for:
- People with commercial insurance. Even partial coverage drops the effective cost below compounded. Sesame Care can route the prescription through your insurance.
- Anyone who wants FDA oversight badly enough to pay $50–200/mo extra. This is a real preference, not a bug.
- Long-term users. The 12-month subscription at $249/mo is the sleeper deal of the year — cheaper than Sprout's compounded offering for FDA-approved medicine.
- People who want a pen, not a vial. Brand-name pens are pre-calibrated. Compounded vials require drawing into a syringe.
Who should skip Wegovy and go compounded
- Budget-first shoppers. $146/mo is still $2,400+ cheaper per year.
- Format-flexibility seekers. Novo sells pens. Compounded programs sell drops, lozenges, tablets, and vials. SHED leads the format diversity ranking.
- Cash-only patients without insurance. No coverage = no copay-card rescue = full $349. Compounded wins.
- Tirzepatide preferrers. Wegovy is semaglutide. If you want tirzepatide (stronger weight loss in trials), compounded programs like Synergy Rx and MEDVi offer it; Zepbound starts at $299/mo for 2.5mg only on LillyDirect.
Sesame Care (Brand)
Get a Wegovy prescription at $29+ per visit. Use insurance or cash-pay at $349 retail.
Check Sesame →Yucca Health
Cheapest verified compounded semaglutide. Injectable only, all-in pricing.
Check Yucca →Synergy Rx
Compounded injectable + oral semaglutide. Month-to-month, no subscription lock.
Check Synergy →What's next
The $349 price is likely a floor for at least 12 months. Novo cut 30% to recapture market share lost to compounded during the shortage-driven compounded boom of 2024–2025. The next pressure point is the IRA-negotiated Medicare price effective January 2027 — rumored around $274 for Ozempic. That will likely force another public cash-pay adjustment. We'll cover it when it hits.
For now, the landscape is stable: brand-name Wegovy at $249–349/mo vs. compounded semaglutide at $146–249/mo. Pick based on your priorities. There's no longer a wrong answer — just different tradeoffs.